Guermouche Hélène, Ravalet Noémie, Gallay Nathalie, Deswarte Caroline, Foucault Amelie, Beaud Jenny, Rault Emmanuelle, Saindoy Emeline, Lachot Sébastien, Martignoles Jean-Alain, Gissot Valérie, Suner Ludovic, Gyan Emmanuel, Delhommeau François, Herault Olivier, Hirsch Pierre
Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, Paris, France.
Assistance Publique-Hôpitaux de Paris, Sorbonne Université, Département d'Hématologie Biologique, Hôpital Saint-Antoine, Paris, France.
Blood Adv. 2020 Aug 11;4(15):3550-3557. doi: 10.1182/bloodadvances.2020001582.
Clonal hematopoiesis (CH) of indeterminate potential has been described in blood samples from large series of patients. Its prevalence and consequences are still not well understood because sequencing methods vary and because most studies were performed in cohorts comprising individuals with nonhematologic diseases. Here, we investigated the frequency of CH in 82 paired bone marrow and blood samples from carefully selected healthy adult volunteers. Forty-one genes known to be mutated in myeloid malignancies were sequenced with a 1% threshold of detection. In bone marrow samples, clones were found in almost 40% of healthy volunteers more than 50 years old. The most frequent mutations were found in DNMT3A and TET2, with 1 individual carrying 3 variants. Variant allele frequencies were highly concordant between blood and bone marrow samples. Blood parameters were normal except for those in 2 individuals: 1 had a mild macrocytosis and 1 had a mild thrombocytosis. Furthermore, no morphologic abnormalities or dysplasia were detected when bone marrow smears were carefully evaluated. Individuals with CH differed from others by age (62.8 vs 38.6 years; P < .0001) and platelet count (294 vs 241 ×109/L; P = .0208), the latter being no more significant when removing the 2 individuals who carried the JAK2 p.V617F mutation. These results confirm that CH is a very common condition in healthy adults over 50 years old. Consequently, the detection of driver myeloid mutations should be interpreted with caution in the absence of cytologic abnormalities in the blood and/or the bone marrow.
在大量患者的血液样本中已描述了具有不确定潜能的克隆性造血(CH)。由于测序方法不同,且大多数研究是在包含非血液系统疾病个体的队列中进行的,其患病率和后果仍未得到很好的理解。在此,我们调查了82对来自精心挑选的健康成年志愿者的骨髓和血液样本中CH的频率。对已知在髓系恶性肿瘤中发生突变的41个基因进行测序,检测阈值为1%。在骨髓样本中,几乎40%的50岁以上健康志愿者中发现了克隆。最常见的突变发生在DNMT3A和TET2基因,有1名个体携带3种变异。血液和骨髓样本中的变异等位基因频率高度一致。除2名个体外,血液参数均正常:1名有轻度大细胞性贫血,1名有轻度血小板增多症。此外,仔细评估骨髓涂片时未发现形态学异常或发育异常。有CH的个体在年龄(62.8岁对38.6岁;P <.0001)和血小板计数(294对241×10⁹/L;P = 0.0208)方面与其他个体不同,在排除携带JAK2 p.V617F突变的2名个体后,后者不再具有统计学意义。这些结果证实CH在50岁以上的健康成年人中是一种非常常见的情况。因此,在血液和/或骨髓中无细胞学异常的情况下,对驱动性髓系突变的检测应谨慎解释。